A Phase 1 interventional study of Nintedanib and Rifampicin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-11-27.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To investigate the effect of the P-gp inducer rifampicin on the pharmacokinetic parameters of nintedanib
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
multiple doses of Rifampicin + single dose of Nintedanib
Drug: Rifampicin · Drug: Nintedanib
single dose of Nintedanib
Drug: Nintedanib
single dose administration
single dose once daily for 7 days
single dose administration
Area Under the Curve From 0 Extrapolated to Infinity (AUC0-∞)
AUC0-∞ represents the Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity. For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
Time frame: 1.5 hour (h) before the first drug administration and 0.5h, 1h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after administration of nintedanib
Maximum Measured Concentration (Cmax)
Cmax represents the maximum concentration of nintedanib in plasma. For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
Time frame: 1.5 hour (h) before the first drug administration and 0.5h, 1h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after administration of nintedanib
Area Under the Curve From 0 to the Last Quantifiable Concentration (AUC0-tz)
AUC0-tz represents the area under the plasma concentration-time curve of nintedanib from 0 to the last quantifiable analyte plasma concentration. For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
Time frame: 1.5 hour (h) before the first drug administration and 0.5h, 1h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after administration of nintedanib
| Milestone | Overall Study |
|---|---|
| Started | 26 |
| Completed | 26 |
| Not completed | 0 |
| Milestone | Overall Study |
|---|---|
| Started | 26 |
| Completed | 25 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
| Milestone | Overall Study |
|---|---|
| Started | 25 |
| Completed | 25 |
| Not completed | 0 |
AUC0-∞ represents the Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity. For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
| ng*h/mL | Nintedanib | Nintedanib + Rifampicin |
|---|---|---|
| Area Under the Curve From 0 Extrapolated to Infinity (AUC0-∞) | 183 ± 36.1 | 89.4 ± 36.8 |
Cmax represents the maximum concentration of nintedanib in plasma. For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
| ng/mL | Nintedanib | Nintedanib + Rifampicin |
|---|---|---|
| Maximum Measured Concentration (Cmax) | 22.1 ± 51.8 | 12.8 ± 43.4 |
AUC0-tz represents the area under the plasma concentration-time curve of nintedanib from 0 to the last quantifiable analyte plasma concentration. For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.
| ng*h/mL | Nintedanib | Nintedanib + Rifampicin |
|---|---|---|
| Area Under the Curve From 0 to the Last Quantifiable Concentration (AUC0-tz) | 173 ± 36.9 | 84.1 ± 38.1 |
Collected over From the first trial drug administration until up to 14 days after last trial drug administration, up to 28 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nintedanib | — | 0/26 (0%) | 5/26 (19.2%) |
| Washout Period | — | 0/26 (0%) | 2/26 (7.7%) |
| Rifampicin | — | 0/25 (0%) | 25/25 (100%) |
| Nintedanib + Rifampicin | — | 0/25 (0%) | 4/25 (16%) |
| Event | Nintedanib | Washout Period | Rifampicin | Nintedanib + Rifampicin |
|---|---|---|---|---|
| ChromaturiaRenal and urinary disorders | 0/26 | 0/26 | 25/25 | 0/25 |
| HeadacheNervous system disorders | 1/26 | 2/26 | 5/25 | 2/25 |
| DiarrhoeaGastrointestinal disorders | 5/26 | 0/26 | 1/25 | 3/25 |
| Faeces discolouredGastrointestinal disorders | 0/26 | 0/26 | 3/25 | 0/25 |
| DizzinessNervous system disorders | 0/26 | 0/26 | 2/25 | 0/25 |
| FlatulenceGastrointestinal disorders | 0/26 | 0/26 | 2/25 | 0/25 |
| FatigueGeneral disorders | 0/26 | 0/26 | 2/25 | 0/25 |
The treated set (TS) consists of all subjects who took at least one dose of study medication.
| Age, Continuous(years) | Overall Study |
|---|---|
| Mean | 37.3 ± 8.7 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 0 |
| Male | 26 |
The record gives a start of Jan 2013, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2014, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib